Synact Pharma large shareholder trading update

SynAct Pharma AB (publ) (”SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnological company focused on treating inflammation through resolution, today announced, that the company has been informed by a large shareholder, that a trade of up to approximately 1 million shares was placed on the market Monday, May 25, due to an operational error between the bank and a private shareholder. The shareholder has informed Synact Pharma that the situation was identified and corrected, and that the order was cancelled by the bank shortly thereafter.